Sunshine Biopharma, Inc. (OTCBB Ticker Symbol: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that they will be presenting scientific data at the American Association for Cancer Research Meeting April 2-6, 2011 in Orlando Florida.
The DNA repair enzyme Topoisomerase II has been recognized in the oncology field as a clinically important therapeutic target for a variety of cancers. Inhibition of Topoisomerase II activity is essential in the fight against aggressive types of cancer, including multi-resistant breast cancer.
Sunshine Biopharma has developed a new compound, Adva-27a, which acts as a specific inhibitor of Topoisomerase II. The data, which will be presented at the Meeting by the Company's research collaborator, Dr. Susannah Gal of Binghamton University (State University of New York), show that Adva-27a and its derivative, Adva-32a, are significantly more effective at killing aggressive cancer cells than Etoposide, the drug currently in use.
Golgi apparatus plays crucial role in enhancing T-cell function against cancer